NTRA
Neutral signalScored 2026-10-26 Drivers: Congress, trend, fundamentals. Moteurs : Congrès, tendance, fondamentaux.
Research, not advice.
À propos
Natera, Inc.
- Nom
- Natera, Inc.
- Secteur
- Healthcare
- Industrie
- Medical - Diagnostics & Research
- Bourse
- NASDAQ
- Capitalisation
- $58.1B
- Employés
- 6,138
- PDG
- Steven Leonard Chapman
- Site web
- https://www.natera.com
- Marché
- BLLNFLGTMYGNPSNLSERAVCYT
Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 162 973 titres (~57 700 001,96 $ US)
- Insiders
- Sheena JonathanRabinowitz MatthewChapman Steven Leonard
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$20,486,157
Avg sell (VWAP, 90d window) $323.68 vs last close $404.90 (+25.1%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$20,417,406 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-10-21
- Liquidity
- Liquid $655,245,925/day · 20d vol
- Last synced
-
2026-10-26 22:35:44
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-21 | Sheena Jonathan | Sell · S | 165 | $416.67 | $68,751 | Form 4 |
| 2026-10-15 | Rabinowitz Matthew | Sell · S · 10b5-1 | 2,000 | $408.24 | $816,471 | Form 4 |
| 2026-10-01 | Chapman Steven Leonard | Sell · S · 10b5-1 | 1,273 | $413.31 | $526,144 | Form 4 |
| 2026-10-01 | Moshkevich Solomon | Sell · S · 10b5-1 | 1,846 | $415.07 | $766,218 | Form 4 |
| 2026-09-23 | Sheena Jonathan | Sell · S · 10b5-1 | 220 | $390.52 | $85,916 | Form 4 |
| 2026-09-16 | Sheena Jonathan | Sell · S · 10b5-1 | 200 | $356.87 | $71,373 | Form 4 |
| 2026-09-15 | Sheena Jonathan | Sell · S · 10b5-1 | 6,000 | $350.07 | $2,100,431 | Form 4 |
| 2026-09-15 | Rabinowitz Matthew | Sell · S · 10b5-1 | 1,813 | $341.41 | $618,970 | Form 4 |
| 2026-09-14 | Rabinowitz Matthew | Sell · S · 10b5-1 | 4,064 | $342.51 | $1,391,947 | Form 4 |
| 2026-09-11 | Rabinowitz Matthew | Sell · S · 10b5-1 | 1,300 | $329.62 | $428,512 | Form 4 |
| 2026-09-02 | Moshkevich Solomon | Sell · S · 10b5-1 | 15,160 | $326.89 | $4,955,713 | Form 4 |
| 2026-09-01 | Chapman Steven Leonard | Sell · S · 10b5-1 | 1,698 | $320.99 | $545,041 | Form 4 |
| 2026-09-01 | Moshkevich Solomon | Sell · S · 10b5-1 | 600 | $321.91 | $193,144 | Form 4 |
| 2026-08-10 | Fesko John | Sell · S · 10b5-1 | 6,517 | $321.53 | $2,095,411 | Form 4 |
| 2026-08-10 | Sheena Jonathan | Sell · S · 10b5-1 | 6,000 | $325.32 | $1,951,942 | Form 4 |
| 2026-08-07 | Rabinowitz Matthew | Sell · S · 10b5-1 | 2,000 | $320.90 | $641,800 | Form 4 |
| 2026-08-07 | Sheena Jonathan | Sell · S · 10b5-1 | 489 | $320.90 | $156,920 | Form 4 |
| 2026-08-04 | Brophy Michael Burkes | Sell · S · 10b5-1 | 478 | $274.22 | $131,077 | Form 4 |
| 2026-08-03 | Brophy Michael Burkes | Sell · S · 10b5-1 | 317 | $267.99 | $84,953 | Form 4 |
| 2026-08-03 | Chapman Steven Leonard | Sell · S · 10b5-1 | 612 | $268.22 | $164,150 | Form 4 |
| 2026-08-03 | Fesko John | Sell · S · 10b5-1 | 295 | $267.99 | $79,057 | Form 4 |
| 2026-08-03 | Moshkevich Solomon | Sell · S · 10b5-1 | 128 | $268.70 | $34,393 | Form 4 |
| 2026-08-03 | RABINOWITZ DANIEL | Sell · S · 10b5-1 | 334 | $267.99 | $89,508 | Form 4 |
| 2026-08-03 | Rabinowitz Matthew | Sell · S · 10b5-1 | 731 | $267.99 | $195,900 | Form 4 |
| 2026-08-03 | Sheena Jonathan | Sell · S · 10b5-1 | 109 | $267.99 | $29,211 | Form 4 |
| 2026-07-29 | Brophy Michael Burkes | Sell · S · 10b5-1 | 1,863 | $249.38 | $464,595 | Form 4 |
| 2026-07-28 | Brophy Michael Burkes | Sell · S · 10b5-1 | 170 | $254.33 | $43,237 | Form 4 |
| 2026-07-28 | Chapman Steven Leonard | Sell · S · 10b5-1 | 3,580 | $254.07 | $909,572 | Form 4 |
| 2026-07-28 | Fesko John | Sell · S · 10b5-1 | 931 | $254.07 | $236,540 | Form 4 |
| 2026-07-28 | Moshkevich Solomon | Sell · S · 10b5-1 | 1,204 | $254.07 | $305,901 | Form 4 |
| 2026-07-28 | RABINOWITZ DANIEL | Sell · S · 10b5-1 | 1,003 | $254.07 | $254,833 | Form 4 |
| 2026-07-28 | Sheena Jonathan | Sell · S · 10b5-1 | 191 | $254.07 | $48,527 | Form 4 |
| 2026-07-27 | Brophy Michael Burkes | Sell · S · 10b5-1 | 782 | $260.49 | $203,704 | Form 4 |
| 2026-07-27 | Chapman Steven Leonard | Sell · S · 10b5-1 | 2,190 | $260.49 | $570,475 | Form 4 |
| 2026-07-27 | Fesko John | Sell · S · 10b5-1 | 782 | $260.49 | $203,704 | Form 4 |
| 2026-07-27 | Moshkevich Solomon | Sell · S · 10b5-1 | 1,010 | $260.49 | $263,096 | Form 4 |
| 2026-07-27 | RABINOWITZ DANIEL | Sell · S · 10b5-1 | 884 | $260.49 | $230,274 | Form 4 |
| 2026-07-27 | Rabinowitz Matthew | Sell · S · 10b5-1 | 1,718 | $260.49 | $447,523 | Form 4 |
| 2026-07-27 | Sheena Jonathan | Sell · S · 10b5-1 | 288 | $260.49 | $75,021 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2025-09-22 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
| 2025-08-22 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
| 2025-07-22 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2024-11-20 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
| 2023-04-10 | Daniel Goldman | Sale | $1,001 - $15,000 |
| 2023-03-06 | Daniel Goldman | Purchase | $1,001 - $15,000 |
Signal
Neutral signalScored 2026-10-26 Drivers: Congress, trend, fundamentals. Moteurs : Congrès, tendance, fondamentaux.
NTRA presents a solid liquidity foundation (score 85) and improving fundamentals (score 65), but the catalyst score is weak (35) driven by heavy insider selling of $57.7M with zero buys, which materially undermines…
The first sentence of the analysis written for NTRA on 2026-10-26 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Congress Supports a bullish reading. 2 purchase disclosures year to date
- Timing Supports a bullish reading. Interesting trend — weekly bias up
- Financial indicators Unavailable or mixed. Current ratio 3.39 · operating margin -13% — readings disagree
Suggested stop 371.90, nearest stored support minus 0.5 ATR(8.2% under the last close). Reward/risk to the next stored resistance is 0.99. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Recent news
- 2026-10-26 Which Healthcare ETF Is the Better Buy: Invesco’s Broad RSPH or First Trust’s Biotech FBT? FBT has outperformed RSPH by a wide margin recently. The question is whether you want to own the fund that won last year or the one built to hold up over many years.
- 2026-10-26 Natera Shares Real-World Analyses and Data at ASN Kidney Week 2026, Highlighting the Critical Need for Genetic Testing with Renasight™ AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced new data that was recently presented at the American Society of Nephrology (ASN) Kidney Week 2026, highlighting the unique value genetic testing can provide for patients with CKD. These 18 abstracts, including three oral presentations, add to the growing support for Renasight, Natera''s genetic test for CKD. Among the key findings were data from a large, real-worl.
- 2026-10-25 Stanley Druckenmiller Has Bet Big on This 1 Healthcare Stock. Here''s Why I Disagree. Druckenmiller owns a large stake in Natera. The company is growing quickly by disrupting the healthcare testing market.
- 2026-10-23 Here Are Friday’s Top Wall Street Analyst Research Calls: Deckers Outdoor, Globe Life, Guardant Health, Hess Midstream LP, Kimberly-Clark, Natera, NVR, SpaceX, Thermo Fisher Scientific, and More A wild Thursday saw Treasury yields crater, oil surge past $111, crypto liquidations top $431 million, and Meta''s cash flow surprise rattle markets. Now analysts are reshuffling their calls on some of the week''s most closely watched names.
- 2026-10-22 Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy? Both of these ETFs look the part, but only one is truly the better buy for investors.
- 2026-10-21 Natera Partners With TransCode to Advance Colorectal Cancer Trial NTRA partners with TransCode Therapeutics to use Signatera MRD testing in a Phase 2a colorectal cancer trial, aiming to accelerate enrollment and research.
- 2026-10-19 2,138 Natera, Inc. $NTRA Shares Acquired by SteelPeak Wealth LLC SteelPeak Wealth LLC grew its position in Natera, Inc. (NASDAQ: NTRA) by 81.3% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,767 shares of the medical research company''s stock after acquiring an additional 2,138 shares during the quarter.
- 2026-10-18 ESMO 2026 Presentations Deepen the Evidence Base for Natera''s Oncology Portfolio and Leadership in Ultrasensitive MRD Technology [url="]Natera, Inc.[/url] (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that 20 abstracts featuring its technology wi
- 2026-10-18 ESMO 2026 Presentations Deepen the Evidence Base for Natera''s Oncology Portfolio and Leadership in Ultrasensitive MRD Technology AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that 20 abstracts featuring its technology will be presented at the 2026 European Society for Medical Oncology (ESMO) Annual Congress, taking place October 23–26 in Madrid, Spain.New evidence highlights the power of Natera''s latest ultrasensitive molecular residual disease (MRD) technology, Signatera Genome with Phased and Structural Variants, which has demonstrat.
- 2026-10-15 Natera (NTRA) Price Forecast: Bullish Trend Holds as Next Leg Looms Natera shares consolidate after a 76% rally, holding key moving-average support as traders watch for a breakout above $437.41 to extend the bullish trend.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 64.8% | 60.3% | 45.5% | 44.4% | 49.1% | |
| Ebit Margin | -11.4% | -10.6% | -39.0% | -65.5% | -74.0% | |
| Ebitda Margin | -9.6% | -8.7% | -36.7% | -63.5% | -72.2% | |
| Operating Profit Margin | -13.4% | -13.1% | -41.2% | -66.0% | -74.8% | |
| Pretax Profit Margin | -11.6% | -11.2% | -40.1% | -66.7% | -75.3% | |
| Continuous Operations Profit Margin | -9.0% | -11.2% | -40.2% | -66.8% | -75.4% | |
| Net Profit Margin | -9.0% | -11.2% | -40.2% | -66.8% | -75.4% | |
| Bottom Line Profit Margin | -9.0% | -11.2% | -40.2% | -66.8% | -75.4% | |
| Current Ratio | 3.393 | 3.999 | 4.096 | 3.903 | 4.993 | |
| Quick Ratio | 3.238 | 3.869 | 3.963 | 3.789 | 4.870 | |
| Solvency Ratio | -0.207 | -0.343 | -0.607 | -0.771 | -0.790 | |
| Cash Ratio | 2.439 | 2.748 | 2.090 | 1.501 | 0.385 | |
| Price To Earnings Ratio | -150.717 | -103.464 | -16.571 | -7.212 | -17.925 | |
| Price To Earnings Growth Ratio | 230.597 | 1.738 | 0.516 | -1.044 | -0.215 | |
| Forward Price To Earnings Growth Ratio | 230.597 | 1.738 | 0.516 | -1.044 | -0.215 | |
| Price To Earnings Diluted Ratio | -150.717 | -103.464 | -16.571 | -7.212 | -17.925 | |
| Price To Earnings Diluted Growth Ratio | 230.597 | 1.738 | 0.516 | -1.044 | -0.215 | |
| Price To Book Ratio | 18.291 | 16.515 | 9.412 | 5.601 | 12.945 | |
| Price To Sales Ratio | 13.582 | 11.635 | 6.654 | 4.819 | 13.521 | |
| Price To Free Cash Flow Ratio | 287.055 | 285.132 | -25.173 | -8.249 | -22.477 | |
| Price To Operating Cash Flow Ratio | 145.477 | 145.528 | -29.169 | -9.161 | -25.228 | |
| Debt To Assets Ratio | 0.085 | 0.113 | 0.307 | 0.320 | 0.321 | |
| Debt To Equity Ratio | 0.125 | 0.157 | 0.578 | 0.632 | 0.608 | |
| Debt To Capital Ratio | 0.111 | 0.135 | 0.366 | 0.387 | 0.378 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.270 | 0.285 | 0.300 | |
| Financial Leverage Ratio | 1.465 | 1.389 | 1.884 | 1.976 | 1.893 | |
| Working Capital Turnover Ratio | 2.209 | 1.711 | 1.169 | 0.924 | 0.813 | |
| Operating Cash Flow Ratio | 0.488 | 0.394 | -0.804 | -1.390 | -1.531 | |
| Operating Cash Flow Sales Ratio | 0.093 | 0.080 | -0.228 | -0.526 | -0.536 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.507 | 0.510 | 1.159 | 1.111 | 1.122 | |
| Debt Service Coverage Ratio | -1.903 | -1.634 | -4.278 | -5.819 | -7.748 | |
| Interest Coverage Ratio | -76.164 | -20.804 | -35.310 | -58.058 | -56.373 | |
| Short Term Operating Cash Flow Coverage Ratio | 2.680 | 1.688 | -3.072 | -5.370 | -6.698 | |
| Operating Cash Flow Coverage Ratio | 1.004 | 0.725 | -0.559 | -0.967 | -0.844 | |
| Capital Expenditure Coverage Ratio | 2.028 | 2.042 | -6.300 | -9.047 | -8.171 | |
| Dividend Paid And Capex Coverage Ratio | 2.028 | 2.042 | -6.300 | -9.047 | -8.171 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -138.116 | -128.205 | -17.605 | -7.552 | -19.423 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 64.8% | ▲4.5% | ▲12.0% |
| Ebit Margin | -11.5% | ▼-0.9% | ▲28.6% |
| Ebitda Margin | -9.6% | ▼-0.8% | ▲28.6% |
| Operating Profit Margin | -13.4% | ▼-0.3% | ▲28.3% |
| Pretax Profit Margin | -11.6% | ▼-0.4% | ▲29.4% |
| Continuous Operations Profit Margin | -9.0% | ▲2.2% | ▲31.5% |
| Net Profit Margin | -9.0% | ▲2.2% | ▲31.5% |
| Bottom Line Profit Margin | -9.0% | ▲2.2% | ▲31.5% |
| Current Ratio | 3.393 | ▼-0.606 | ▼-0.684 |
| Quick Ratio | 3.237 | ▼-0.631 | ▼-0.708 |
| Solvency Ratio | -0.207 | ▲0.136 | ▲0.337 |
| Cash Ratio | 2.439 | ▼-0.309 | ▲0.606 |
| Price To Earnings Ratio | -150.717 | ▼-47.253 | ▼-91.539 |
| Price To Earnings Growth Ratio | 230.597 | ▲228.859 | ▲184.279 |
| Forward Price To Earnings Growth Ratio | 230.597 | ▲228.859 | ▲184.279 |
| Price To Earnings Diluted Ratio | -150.717 | ▼-47.253 | ▼-91.539 |
| Price To Earnings Diluted Growth Ratio | 230.597 | ▲228.859 | ▲184.279 |
| Price To Book Ratio | 18.291 | ▲1.775 | ▲5.738 |
| Price To Sales Ratio | 13.582 | ▲1.947 | ▲3.540 |
| Price To Free Cash Flow Ratio | 287.055 | ▲1.922 | ▲183.797 |
| Price To Operating Cash Flow Ratio | 145.477 | ▼-0.050 | ▲99.988 |
| Debt To Assets Ratio | 0.086 | ▼-0.027 | ▼-0.144 |
| Debt To Equity Ratio | 0.125 | ▼-0.031 | ▼-0.295 |
| Debt To Capital Ratio | 0.111 | ▼-0.024 | ▼-0.164 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | ▼-0.171 |
| Financial Leverage Ratio | 1.465 | ▲0.075 | ▼-0.257 |
| Working Capital Turnover Ratio | 2.209 | ▲0.498 | ▲0.844 |
| Operating Cash Flow Ratio | 0.488 | ▲0.094 | ▲1.056 |
| Operating Cash Flow Sales Ratio | 0.093 | ▲0.013 | ▲0.317 |
| Free Cash Flow Operating Cash Flow Ratio | 0.507 | ▼-0.004 | ▼-0.375 |
| Debt Service Coverage Ratio | -1.903 | ▼-0.269 | ▲2.373 |
| Interest Coverage Ratio | -76.164 | ▼-55.360 | ▼-26.822 |
| Short Term Operating Cash Flow Coverage Ratio | 2.680 | ▲0.992 | ▲4.835 |
| Operating Cash Flow Coverage Ratio | 1.004 | ▲0.279 | ▲1.132 |
| Capital Expenditure Coverage Ratio | 2.027 | ▼-0.015 | ▲5.917 |
| Dividend Paid And Capex Coverage Ratio | 2.027 | ▼-0.015 | ▲5.917 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -138.117 | ▼-9.911 | ▼-75.936 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $31.32B | $19.74B | $7.20B | $3.95B | $8.46B | |
| Enterprise value | $30.46B | $18.98B | $7.00B | $3.93B | $8.77B | |
| EV / Sales | 13.21x | 11.19x | 6.47x | 4.79x | 14.02x | |
| EV / Op. cash flow | 141.47x | 139.94x | -28.36x | -9.12x | -26.16x | |
| EV / Free cash flow | 279.16x | 274.18x | -24.47x | -8.21x | -23.31x | |
| EV / EBITDA | -138.12x | -128.21x | -17.61x | -7.55x | -19.42x | |
| Net debt / EBITDA | 3.91x | 5.12x | 0.50x | 0.04x | -0.69x | |
| Current ratio | 3.39x | 4.00x | 4.10x | 3.90x | 4.99x | |
| Income quality | -1.03x | -0.71x | 0.57x | 0.79x | 0.71x | |
| Graham net-net | $4 | $6 | $4 | $4 | $5 | |
| Tax burden | 77.6% | 100.4% | 100.1% | 100.2% | 100.1% | |
| Interest burden | 101.5% | 106.0% | 103.0% | 101.7% | 101.8% | |
| Working capital | $1.06B | $1.03B | $951.3M | $901.3M | $874.2M | |
| Invested capital | $1.92B | $1.28B | $1.12B | $1.07B | $998.7M | |
| Return on assets | -8.3% | -11.5% | -30.2% | -39.3% | -38.1% | |
| Operating ROA | -14.9% | -14.3% | -31.5% | -41.1% | -43.2% | |
| Return on tangible assets | -10.4% | -11.5% | -30.2% | -39.3% | -38.1% | |
| Return on equity | -12.2% | -15.9% | -56.8% | -77.6% | -72.2% | |
| Return on invested capital | -11.1% | -15.8% | -36.4% | -46.2% | -43.6% | |
| Return on capital employed | -15.0% | -16.9% | -39.3% | -49.9% | -46.0% | |
| Earnings yield | -0.7% | -1.0% | -6.0% | -13.9% | -5.6% | |
| Free cash flow yield | 0.3% | 0.4% | -4.0% | -12.1% | -4.4% | |
| Capex / Op. cash flow | 49.3% | 49.0% | -15.9% | -11.1% | -12.2% | |
| Capex / Depreciation | 244.2% | 214.5% | 162.7% | 285.6% | 364.6% | |
| Capex / Sales | 4.6% | 3.9% | 3.6% | 5.8% | 6.6% | |
| SG&A / Sales | 51.0% | 49.6% | 57.1% | 71.8% | 81.7% | |
| R&D / Sales | 27.1% | 23.8% | 29.6% | 38.6% | 42.2% | |
| Stock comp / Sales | 15.4% | 16.2% | 17.7% | 18.6% | 18.4% | |
| Intangibles / Total assets | 20.5% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 47d | 68d | 94d | 109d | 71d | |
| Days payables outstanding | 15d | 19d | 9d | 25d | 31d | |
| Operating cycle | 78d | 92d | 119d | 137d | 102d | |
| Cash conversion cycle | 63d | 73d | 110d | 112d | 71d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years